세계의 대사 검사 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Global Metabolic Testing Market size is estimated at USD 558.74 million in 2024, and is expected to reach USD 796.93 million by 2029, growing at a CAGR of 7.36% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the metabolic testing market due to increased sedentary lifestyles and reduced physical activities due to the lockdown. For instance, as per the article published in March 2021 in MedRxiv journal, the COVID-19 epidemic increased sedentary lifestyles and unhealthy dietary habits. As a result of the increase in metabolic diseases caused by unhealthy dietary habits, the demand for metabolic testing soared during the pandemic. In the post-pandemic situation, as the restrictions were lifted, the market is likely to witness growth due to the rise in obesity and other metabolic disorders coupled with the advancements in metabolic testing.

The market is primarily driven by the growing incidence and prevalence rate of various lifestyle-related diseases such as heart diseases, hypertension, high cholesterol, diabetes, and obesity worldwide and technological advances in metabolic testing. For instance, as per the World Obesity Atlas 2022, by 2030, it is predicted that 1 in 5 women and 1 in 7 men are likely to be living with obesity, equating to over 1 billion people globally.

Similarly, as per America's Health Rankings, 35.7% of adults reported having their cholesterol checked and considered high in 2021 in the United States. As per the same source, 14.2% of adults reported by a health professional that they had angina or coronary heart disease, a heart attack or myocardial infarction, or a stroke in West Virginia in 2021. Thus, the high burden of diseases is expected to increase the demand for metabolic testing. Additionally, as per the May 2021 data from the WHO, about 1.13 billion people worldwide have hypertension, of which two-thirds live in low- and middle-income countries. Thus, with the growing prevalence of such lifestyle diseases, the demand for metabolic testing is expected to increase as a growing trend toward monitoring health parameters.

Factors such as a huge pool of obese patients, an increase in the prevalence of metabolic disorders, technological advancements, and rising health and fitness consciousness are expected further to augment the market's growth over the forecast period. For instance, in February 2022, AliveCor launched KardiaMobile Card, the slimmest, most convenient personal ECG device which fits easily into any wallet and delivers a medical-grade, single-lead ECG in 30 seconds. Additionally, numerous awareness programs run globally to emphasize the significance of testing and treatment options for metabolic diseases. For instance, in May 2022, the American Liver Foundation conducted a countrywide screening and public awareness program, 'Think Liver Think Life,' to test at-risk children and adults in all 50 states over the next five years to address the increase in fatty liver disease.

Therefore, the increasing prevalence of lifestyle diseases such as cardiovascular disease, obesity, and diabetes, technological advancements, and healthcare expenditure are the key driving factors in the metabolic testing market. However, the high cost of Equipment and Software restrains the market growth over the forecast period.

Metabolic Testing Market Trends

Body Composition Analyzers are Expected to Hold a Significant Market Share in the Market Over the Forecast Period

Body composition analyzers (BCA) measure various body components and offer their respective values at the examination location. Body composition analyzers have numerous uses in sports and medical research, particularly causal association studies in anthropology, nutrition, epidemiology, etc. The segment is driven by rising in the prevalence of lifestyle diseases and product launches by the key market players.

According to the World Obesity Atlas 2022, 40 million females will be diagnosed with obesity by 2030 in India. Furthermore, because emerging countries have a larger obesity illness burden, the market for fat monitoring equipment such as body composition analyzers is likely to rise.

Furthermore, studies demonstrating the efficacy of body composition analyzers expand the opportunities for segment growth because people are becoming more aware of their nutritional intake, increasing the demand for the BCA, thereby fueling the market growth over the forecast period. For instance, as per the article published in May 2022 in PubMed, the study depicted the importance of assessing body composition and its usefulness in predicting cardiopulmonary fitness as an indicator of overall health. Furthermore, implementing important strategic plans such as mergers and acquisitions to extend the product portfolio and regional presence will fuel market growth. For instance, in April 2022, InBody introduced the BWA 2.0 body water analyzer, which gives statistics on how body composition and body water affect well-being. This new professional-grade device expands on the InBody S10's outputs, which use attachable electrodes to assess body composition and body water in individuals who are immobilized or have amputated limbs. Therefore, the increasing prevalence of lifestyle diseases such as cardiovascular disease, obesity, and diabetes, technological advancements, and body composition analyzer product launches are the key driving factors in the segment growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to hold a significant market share in the metabolic testing market due to the robust healthcare infrastructure, technological advancements in metabolic testing, increase in awareness of metabolic diseases and surge in lifestyle diseases such as cardiovascular diseases, obesity, and type 2 diabetes in the region. For instance, as per the IDF Diabetes Atlas 10th edition published in 2021, the number of people living with diabetes in Mexico was 14,123.2 thousand in 2021. This number is estimated to increase to 17,062.7 thousand by 2045. Similarly, according to the same source, the diabetic population in the United States was 32,215.3 thousand in 2021. This figure is expected to rise to 36,289.9 thousand by 2045. In Canada, the number of diabetics reached 2,974 thousand in 2021. This figure is expected to rise to 3,468.5 thousand by 2045 in Canada. Hence, such an increase in metabolic diseases like diabetes is anticipated to increase the demand for metabolic testing in the region, thereby driving market growth over the forecast period.

Additionally, as per the CDC January 2023 update, nearly half of the adults in the United States (47%, or 116 million) have hypertension, defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension. Moreover, investments in developing metabolic devices are expected to fuel the market growth in the studies region. For instance, in December 2022, Lumen raised USD 62M for its handheld weight-loss hardware. Lumen developed a handheld hardware device that contains a built-in sensor that measures the level of CO2 produced to determine 'metabolic fuel usage', whether the body is burning carbs or fat for fuel. It connects to a smartphone and the associated app gives personalized food, exercise, and sleep recommendations. Hence, due to the rising incidence of lifestyle disorders like diabetes, obesity, and heart disease as well as an increase in investments and fundraising to develop metabolic devices, North America is expected to hold a notable share in the market studied over the forecast period.

Metabolic Testing Industry Overview

The metabolic testing market is fragmented in nature due to several market players. In terms of market share, a few major players dominate the market. Some of the key companies in the market are MGC Diagnostics Corporation, COSMED Srl, CORTEX Biophysik GmbH, General Electric Company (GE Healthcare), KORR Medical Technologies, Inc, CareFusion Corporation, Geratherm Medical AG, OSI Systems, Inc, AEI Technologies, Inc, and Parvo Medics.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence of Lifestyle Diseases
  • 4.2.2 Technological Advancements in Metabolic Testing
• 4.3 Market Restraints
  • 4.3.1 High Cost of Equipment and Software
  • 4.3.2 Poor Reimbursement Policies
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

• 5.1 By Equipment Type
  • 5.1.1 Body Composition Analyzers
  • 5.1.2 Cardiopulmonary Exercise Testing (CPET) Systems
  • 5.1.3 ECG Systems
  • 5.1.4 Metabolic Carts
  • 5.1.5 Others
• 5.2 By Application
  • 5.2.1 Critical Care
  • 5.2.2 Lifestyle Diseases
• 5.3 By End User
  • 5.3.1 Hospitals and Clinics
  • 5.3.2 Sports Training Centers
  • 5.3.3 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 MGC Diagnostics Corporation
  • 6.1.2 COSMED srl
  • 6.1.3 CORTEX Biophysik GmbH
  • 6.1.4 General Electric Company (GE Healthcare)
  • 6.1.5 KORR Medical Technologies, Inc
  • 6.1.6 Becton, Dickinson and Company (CareFusion Corporation)
  • 6.1.7 Geratherm Medical AG
  • 6.1.8 OSI Systems, Inc
  • 6.1.9 AEI Technologies, Inc
  • 6.1.10 Parvo Medics
  • 6.1.11 Inbody Co. Ltd
  • 6.1.12 Koninklijke Philips NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS